R&D
2nd Peptide-Based Therapeutics Summit banner
Partner Content

2nd Peptide-Based Therapeutics Summit

With Merck’s oral PCSK9 inhibitor demonstrating strong phase 3 trial results, J&J’s IL23R antagonist peptide continuing its phase 3 journey, and Chugai advancing peptides into the intracellular

Debates & Insights

News

Press Releases

Newsletters and Deep Dive
digital magazine

Views & Analysis

Webinars

Podcasts

Video

White Papers

Event

Partner Content

Debates & Insight